Kymera Therapeutics stock fell 3.52 percent on October 6

Published on 10/07/2026 at 06:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera Therapeutics stock stood at USD 105.98 on October 6, 2026, 18.51 percent below the 52-week high. Q2 revenue reached USD 65.0 million, up 465.2 percent year over year.

KYMR, US5015751044, Illustration mit AI erstellt.

Kymera Therapeutics (ISIN US5015751044) was last at USD 105.98 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 3.52 percent from USD 109.85. The latest company-specific checkpoint is its Q2 2026 report, released on August 5.

Q2 revenue surged on collaborations

MarketBeat reported that Kymera posted Q2 revenue of USD 65.0 million, up 465.2 percent from the same quarter a year earlier and above the USD 32.78 million consensus estimate. The company reported an adjusted loss of USD 0.62 per share, better than the USD 0.71 consensus loss and the USD 0.95 loss in the prior-year quarter.

The revenue increase was paired with a quarterly net loss of USD 61.211 million, while operating cash flow was negative USD 54.065 million in Q2 2026. For a clinical-stage biotechnology company, the figures show how collaboration-related revenue can change one quarter's income statement without removing the funding demands of late-stage development.

Analysts keep targets above USD 105.98

MarketBeat lists a Moderate Buy consensus based on 1 Strong Buy, 22 Buy, 2 Hold and 1 Sell ratings, with an average target of USD 134.46. That target lies 26.87 percent above the USD 105.98 quote.

As Markets Insider reported on October 5, 2026, Citi analyst Geoff Meacham raised the target from USD 135 to USD 150 and kept a Buy rating. Citi tied the change to the expected KT-621 atopic dermatitis readout by the end of 2026.

Stock stays below its yearly high

At USD 105.98, Kymera sat below its 50-day average of USD 114.62 and above its 200-day average of USD 99.27 on October 6, according to MarketBeat. The quote was 18.51 percent below the 52-week high of USD 130.05 and 91.63 percent above the 52-week low of USD 55.26.

For investors, the central tension is visible in the numbers: Q2 revenue accelerated sharply, while clinical progress and future data remain important to the valuation. The October 6 market capitalization was USD 8.7 billion, with volume of 960,689 shares.

Kymera stock remains data driven

Kymera Therapeutics was last at USD 105.98 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with the stock positioned between its 50-day and 200-day averages as investors assess the next pipeline milestone.